ABCG2 Gene Expression in Non-Small Cell Lung Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• ATP-binding cassette subfamily G member 2 (ABCG2), also known as breast cancer resistance protein (BCRP), is implicated in multidrug resistance and cancer stem cell markers.
• ABCG2's role in non-small cell lung cancer (NSCLC) development, progression, and patient outcomes requires further elucidation.

Purpose of the Study:

• To investigate the impact of ABCG2 gene expression on NSCLC development, disease course, and patient prognosis.
• To analyze ABCG2 expression in NSCLC patients' blood and its correlation with clinical parameters.
• To explore ABCG2 protein interactions and their association with drug resistance.

Main Methods:

• Utilized multiple bioinformatics databases (TIMER 2.0, UALCAN, TNMplot, MEXPRESS, cBioPortal, MethSurv, KM Plotter, STRING, ShinyGO 0.80) for in silico analysis of lung cancer datasets.
• Assessed ABCG2 expression in blood samples from 50 NSCLC patients using real-time PCR.
• Analyzed CpG island methylation affecting NSCLC prognosis.

Main Results:

• ABCG2 was expressed at low levels in NSCLC and did not correlate with clinical aggressiveness.
• Higher ABCG2 expression was associated with improved overall survival specifically in lung adenocarcinoma (LUAD) patients.
• No significant changes in blood ABCG2 expression levels were observed during the diagnostic-therapeutic procedure in NSCLC patients.
• In silico analysis revealed that most ABCG2 protein interactors are linked to drug resistance mechanisms.

Conclusions:

• ABCG2 significantly influences lung cancer patient survival and immunotherapy effectiveness, particularly concerning immune cell infiltration.
• Findings suggest potential for personalized medicine strategies in NSCLC based on ABCG2 expression and bioinformatics data.
• ABCG2's role in LUAD prognosis warrants further investigation for targeted therapeutic approaches.